Phase 2 study of danicopan in patients with paroxysmal nocturnal hemoglobinuria with an inadequate response to eculizumab

Paroxysmal nocturnal hemoglobinuria (PNH) is characterized by uncontrolled terminal complement activation and subsequent intravascular hemolysis (IVH). C5 inhibitors prevent membrane attack complex formation, but patients may experience extravascular hemolysis (EVH) and continue to require blood tra...

Descripción completa

Detalles Bibliográficos
Autores principales: Kulasekararaj, Austin G., Risitano, Antonio M., Maciejewski, Jaroslaw P., Notaro, Rosario, Browett, Peter, Lee, Jong Wook, Huang, Mingjun, Geffner, Michael, Brodsky, Robert A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2021
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8602931/
https://www.ncbi.nlm.nih.gov/pubmed/34314483
http://dx.doi.org/10.1182/blood.2021011388

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8602931/
https://www.ncbi.nlm.nih.gov/pubmed/34314483
http://dx.doi.org/10.1182/blood.2021011388

Ejemplares similares